Skip to content
AnalystLens

BeOne Medicines Ltd. 8-K Report, Financial Results (Aug 7, 2024)

Reports
Earnings & Results·Other Events·Exhibits & Filings
Filing Date
Filed August 7, 2024
Period End
August 7, 2024
Securities
ONCBEIGF
In the record · 2016–202610-K1310-Q328-K284

ONC filed 13 annual reports (10-K), 32 quarterly reports (10-Q) and 284 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Jun ’22Jun ’22
  4. Leadership change8-K · Jun ’26Jun ’26

01—Abstract

Summary

Summary of the 8-K filed August 7, 2024. Cited figures are marked; the original filing is the authoritative source.

This 8-K from BeiGene, Ltd. (later renamed BeOne Medicines; the filing itself uses the BeiGene name) furnishes second-quarter 2024 results and corporate updates.

Total revenue rose 56% year over year to $929 milliona, driven by BRUKINSA, whose global revenue reached $637 million (up 107%). Product revenue grew 66% to $921 million, and gross margin on product sales improved to 85% from 83%. The most significant development for investors is the first quarter of positive non-GAAP operating income, at $48 million versus a $193 million loss a year earlier.

GAAP operating loss narrowed 66% to $107 million, and GAAP net loss fell to $120 millionb, or $(1.15) per ADS, from $381 million. The quarter's cash burn also improved sharply. Cash used in operations was $96 million, compared with $294 million a year earlier, but cash, cash equivalents and restricted cash still declined to $2.62 billion from $3.19 billion at year-end 2023, and debt increased to $1.04 billion.

The company also flagged a regulatory setback: FDA deferred its decision on tislelizumab in first-line esophageal squamous cell carcinoma because of delays in scheduling clinical site inspections. Management also announced a proposal to redomicile from the Cayman Islands to Switzerland, which is subject to shareholder approval, and opened a $800 millionc flagship U.S. biologics manufacturing facility in New Jersey. The pipeline is broad, with more than 15 solid tumor molecules in development, and the hematology franchise is central to the growth story.

Sonrotoclax (BCL2 inhibitor) has completed enrollment in a global Phase 2 trial in relapsed/refractory mantle cell lymphoma, and the BTK degrader BGB-16673 is advancing toward Phase 3 entry expected in late 2024 or early 2025. Investors should weigh the strong top-line momentum and progress toward operating profitability against continued heavy R&D and SG&A spending, the still-large cash balance decline, and the tislelizumab regulatory delay.

02—Key points

Key Highlights

  1. Total revenue of $929 million rose 56% year over year, led by BRUKINSA global revenue of $637 million (up 107%), with U.S. sales of $479 million (up 114%) and Europe sales of $81 million (up 209%).
  2. First quarter of positive non-GAAP operating income: $48 million, compared with a $193 million adjusted operating loss in Q2 2023.
  3. GAAP operating loss narrowed 66% to $107 million, and GAAP net loss improved to $120 million ($(1.15) per ADS) from $381 million a year earlier.
  4. Gross margin on product revenue increased to 85% from 83%, reflecting a higher mix of BRUKINSA.
  5. Cash used in operations fell to $96 million from $294 million, but cash and equivalents declined to $2.62 billion from $3.19 billion at year-end 2023, and debt rose to $1.04 billion.
  6. FDA deferred its decision on tislelizumab for first-line esophageal squamous cell carcinoma, originally targeted for July 2024, due to delays in scheduling clinical site inspections.
  7. Announced a proposed redomiciliation from the Cayman Islands to Basel, Switzerland (subject to shareholder approval) and opened a $800 million flagship U.S. biologics manufacturing facility in Hopewell, New Jersey.

03—Questions

Frequently Asked Questions

  1. Did the company achieve profitability in Q2 2024?

    Only on an adjusted (non-GAAP) basis. Adjusted operating income was $48 million, excluding share-based compensation and depreciation and amortization. On a GAAP basis, the company still reported an operating loss of $107 million and a net loss of $120 million, though both were substantially smaller than a year earlier.

  2. What is driving revenue growth?

    Growth is driven primarily by BRUKINSA, whose global revenue reached $637 million, up 107%. U.S. sales grew 114% to $479 million, supported by share gains in CLL new patient starts, and European sales grew 209% to $81 million across Germany, Italy, Spain, France and the UK. Tislelizumab sales were $158 million, up only 6%, and collaboration revenue fell 81% to $8 million.

  3. What regulatory and corporate risks were disclosed?

    The FDA deferred its decision on tislelizumab in first-line ESCC because of delays in scheduling clinical site inspections, so the approval timing is now uncertain. The proposed redomiciliation from the Cayman Islands to Switzerland requires shareholder approval, and its outcome is not assured.

  4. How is the company's liquidity position?

    Cash, cash equivalents and restricted cash were $2.62 billion at June 30, 2024, down from $3.19 billion at December 31, 2023, while debt increased to $1.04 billion from $886 million. Operating cash burn improved significantly, to $96 million from $294 million in the prior-year quarter, but continued investment and debt levels remain key monitoring points.

  5. What are the next pipeline catalysts?

    Near-term catalysts include a potential first readout of Phase 1 data for the CDK4 inhibitor BGB-43395 in Q4 2024, Phase 3 enrollment starts for sonrotoclax in relapsed/refractory CLL and mantle cell lymphoma and for BGB-16673 in Q4 2024 or Q1 2025, and several tislelizumab lung and esophageal combination readouts expected in 2024.

04—Continue

← View all 8-K filings